TAK-875, a GPR40 agonist, was withdrawn from Phase III clinical trials due to drug-induced liver injury (DILI). Mechanistic studies were conducted to identify potential DILI hazards (covalent binding burden (CVB), hepatic transporter inhibition, mitochondrial toxicity, and liver toxicity in rats) associated with TAK-875. Treatment of hepatocytes with radiolabeled TAK-875 resulted in a CVB of 2.0 mg/day, which is above the threshold of 1 mg/day considered to be a risk for DILI. Covalent binding to hepatocytes was due to formation of a reactive acyl glucuronide (AG) and, possibly, an acyl-CoA thioester intermediate. Formation of TAK-875AG in hepatocytes and/or in vivo was in the order of non-rodents > human (in vitro only) > rat. These data suggest that non-rodents, and presumably humans, form TAK-875AG more efficiently than rats, and that AG-mediated toxicities in rats may only occur at high doses. TAK-875 (1000 mg/kg/day) formed significant amounts of AG metabolite ( 32.7 lM) in rat liver that was associated with increases in ALT (Â4), bilirubin (Â9), and bile acids (Â3.4), and microscopic findings of hepatocellular hypertrophy and single cell necrosis. TAK-875 and TAK-875AG had similar potencies (within 3-fold) for human multi-drug resistant associated protein 2/4 (MRP2/4) and bile salt export pump, but TAK-875AG was exceptionally potent against MRP3 (0.21 lM). Inhibition of MRPs may contribute to liver accumulation of TAK-875AG. TAK-875 also inhibited mitochondrial respiration in HepG2 cells, and mitochondrial Complex 1 and 2 activities in isolated rat mitochondria. In summary, formation of TAK-875AG, and possibly TAK-875CoA in hepatocytes, coupled with inhibition of hepatic transporters and mitochondrial respiration may be key contributors to TAK-875-mediated DILI.
reactive metabolites, inhibition of hepatic transporters, and inhibition of mitochondrial function (Aleo et al., 2014; Schadt et al., 2015) . Liver histopathology observed in non-clinical studies at high multiples above the predicted clinical exposure can also be used as a DILI hazard within the appropriate context.
Formation of reactive metabolites and covalent binding to proteins is one of the most extensively studied of the DILI hazards (Leung et al., 2012; Uetrecht, 2008) . Studies show that drugs with a CVB > 1 mg/day are associated with a high risk for DILI based on in vitro covalent protein binding (Thompson et al., 2012) . It is hypothesized that presentation of a drug-protein complex to T-cells results in immune tolerance as the default response, however, immune activation, and DILI, may be triggered by additional danger signals resulting in upregulation of T-cell co-stimulatory factors (Uetrecht, 2008) . Approaches that break immune tolerance may unmask liver injury, as recently demonstrated by compounds known to form reactive metabolites with a clinical risk of DILI (Mak and Uetrecht, 2015a,b) .
Inhibition of hepatic transporters, specifically the bile salt export pump (BSEP) and multi-drug resistant associated protein 2/3/4 (MRP2/3/4), have been identified as a hazard for cholestatic DILI (Kock et al., 2014) . Bile salts are tightly regulated and are efficiently recirculated via active processes that include biliary efflux via BSEP, re-uptake in ileum via apical sodium-dependent bile acid transporter (ASBT), and uptake in hepatocytes via sodium taurocholate pump (NTCP) and to a lesser extent by organic anion transporter proteins (OATP; Hofmann, 1999; Wagner et al., 2009) . Bile acids are toxic to hepatocytes and adaptive processes, such as efflux via sinusoidal (MRP3/4) and canaliculi (BSEP, MRP2) transporters are important for cellular protection (Rius et al., 2003; Zelcer et al., 2003) . Inhibition of MRPs can cause accumulation of drugs/metabolites that are substrates for the transporters, notably glucuronide metabolites. Therefore, inhibition of BSEP and/or MRP2/3/4 by drugs can be a hazard for DILI because of the potential for accumulation of toxic bile salts or reactive/toxic drugs in hepatocytes.
Injury to mitochondria has also been identified as a hazard for DILI (Fontana, 2014; Pessayre et al., 2012; Thompson et al., 2012) . Drugs or metabolites can indirectly cause mitochondrial injury by inhibiting BSEP resulting in accumulation of bile acids, which can damage mitochondrial membranes (Schulz et al., 2013; Sousa et al., 2015) . It is postulated that this is the mechanism by which BSEP inhibitors, such as Bosentan cause DILI (Fattinger et al., 2001; Woodhead et al., 2014) . Drugs or metabolites can also cause direct injury to mitochondria by inhibiting respiration and/or causing cell stress. Because mitochondria are a major site for fatty acid metabolism (b-oxidation), direct mitochondrial injury may cause DILI by inhibition of b-oxidation leading to accumulation of toxic fatty acids in hepatocytes exemplified by valproate (Silva et al., 2008) . Cell stress secondary to mitochondrial dysfunction may also trigger the release of damage associated molecular patterns (DAMPs) causing activation of the immune system (Boelsterli and Lee, 2014) . These DILI hazards can be integrated qualitatively (Mak and Uetrecht, 2015b; Shah et al., 2015) or quantitatively to assess a compound's overall risk for DILI.
TAK-875, a GPR40 agonist, under development for Type 2 diabetes (Kaku et al., 2015) , was withdrawn from Phase III clinical trials (Kaku et al., 2015 (Kaku et al., , 2016 Takeda Press Release, 2015) due to DILI considered likely to be idiosyncratic in nature. In a 24-week Phase III study (Kaku et al., 2015) , there was a 3% (N ¼ 62) and 6% (N ¼ 63) incidence in ALT > 3xULN in patients given 25 mg and 50 mg TAK-875, respectively, compared with placebo (N ¼ 67). In a larger 52-week Phase III trial (Kaku et al., 2016) , imbalance in ALT was inconclusive because data for placebo were not reported. At a recent disclosure at a FDA-DILI conference an imbalance in ALT was reported in patients treated with 50 mg TAK-875 in a cardiovascular outcome study (Marcinak et al., 2016) . A retrospective characterization of potential DILI hazards was conducted for TAK-875; hazards evaluated included formation of reactive metabolites and covalent protein binding, inhibition of hepatic transporters, liver toxicity signals in animal studies, and mitochondrial toxicity. Identification of the risk factors relevant to TAK-875 hepatotoxicity is important to the design of next generation GPR40 agonists. Although DILI by TAK-875 is not considered to be related to GPR40 pharmacology, the endogenous ligand for this receptor are medium to long-chain free fatty acids (Defossa and Wagner, 2014) , and most GPR40 agonists under investigation are carboxylic acids, therefore formation of a reactive acylglucuronide as well as the other DILI hazards described in these studies could apply to other carboxylic acids being considered for this target. Metabolism of TAK-875 in Rat, Dog, Cynomolgus Monkey (Cyno), and Human Hepatocytes The metabolism of TAK-875 was investigated in cryopreserved hepatocytes from rat, dog, monkey, and human. Briefly, incubations were carried out at a cell concentration of 1 Â 10 6 cells/mL in a total incubation volume of 1.0 mL of Krebs-Henseleit buffer containing 12.5 mM HEPES pH 7.4 (KHB) in glass tubes at 37 C under 5% CO 2 in a humidified incubator with constant shaking. Cells were incubated for 0 or 4 h with 10 lM TAK-875 in triplicates. Diclofenac, at a final concentration of 10 lM was used as a positive control. The cell incubates were quenched with 5 vol of ice-cold acetonitrile (ACN):isopropyl alcohol/1:1 þ 0.1% formic acid, and an aliquot of 240 lL of ammonium formate (pH 3.0, 500 mM) was added to the incubations to stabilize AG metabolites. Following centrifugation samples were analyzed by LC-LTQ/Orbitrap XL (Supplementary, analytical method 1).
MATERIALS AND METHODS

Reagents
Covalent Protein Binding in Hepatocytes
In vitro covalent protein binding studies were performed using cryopreserved human hepatocytes. Preparation of cryopreserved hepatocytes and assessment of viability were conducted as described above. In brief, incubations with hepatocytes were carried out at a cell concentration of 1 Â 10 6 cells, in a total incubation volume of 1.0 mL of KHB in glass tubes at 37 C under 5% CO 2 in a humidified incubator with constant shaking. Human hepatocytes were incubated in triplicate for 0 or 4 h with 10 lM 14 C-TAK-875. Another set of incubates in triplicate were spiked with radiolabeled test compound after 4 h (hepatocytes) for non-specific binding subtraction. The pellets from the protein precipitation were exhaustively extracted 6 times with 5 mL of ACN:isopropyl alcohol/1:1 fortified with 0.1% formic acid and the 5th and 6th solvent extracts was counted to ensure radioactivity was at background levels. The exhaustively washed pellets were solubilized in 5% SDS by heating at 55 C overnight in a shaking water bath. An aliquot of the solubilized pellets was removed and counted using liquid scintillation counter to determine radioactivity bound to protein. Protein determination from individual sample was conducted using the solubilized pellets according to the Pierce BCA Protein Assay (Thermo Scientific, San Jose, CA). The amount of radioactivity in the supernatants and pellets after protein precipitation were converted to parent drug equivalent to give an estimated mass balance of the experiment. Also, the amount of drug equivalents in the protein pellets were scaled to covalent body burden using previously published procedure (Thompson et al., 2012) .
In vivo Metabolism of TAK-875 in Rats, Dogs, and Cynomolgus Monkeys (Cynos) TAK-875 was administered as a single oral dose of 100 mg/kg in rats (n ¼ 3) and 30 mg/kg in dogs (n ¼ 4) or cynos (n ¼ 3) in 0.5% methocel. Blood was collected in K 2 EDTA tubes, processed by centrifugation, and the resulting plasma sample was stabilized with 0.5 M ammonium formate buffer, pH 3.0 (30%, v/v) and stored at -80 C prior to analysis. Exposure to parent and several metabolites (M-I, TAK-875-AG, and TAK-875-TAU), previously described as present in humans given TAK-875 , was determined. Hepatic drug concentrations of TAK-875 and its metabolites were determined in rats and dogs. Liver ($1 g) samples were rinsed with sterile water, blotted dry, and weighed. The tissues were homogenized at a 1:3 ratio of tissue weight to volume of sterile water containing 0.5 M ammonium formate buffer, pH 3.0 (30%, v/v), and homogenates were kept on dry ice and transferred to À80 C freezer prior to analysis.
Bile, sampled from dogs at necropsy, was stabilized with 0.5 M ammonium formate buffer, pH 3.0 (30%, v/v) and stored at -80 C freezer prior to analysis. Protein (plasma, liver, bile) was precipitated with 4 vol of ACN, centrifuged at 3500 rpm for 3 min, and supernatant analyzed (Supplementary, analytical method 3). Toxicokinetic analysis of the plasma concentration data was conducted using Phoenix WinNonlin (Certara USA, Inc, Princeton, NJ).
Investigative Studies in Rats
All animals were maintained at Janssen Pharmaceuticals facilities in accordance with the guidelines established by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and all protocols were approved by the Janssen Animal Care and Use Committee (ACUC). Male Sprague Dawley rats (Charles River Laboratories, Bar Raleigh, NC;
n ¼ 5-6/group) were given TAK-875 by oral gavage as a suspension in 0.5% Methocel at 100, 300, and 1000 mg/kg/day for 5 days or 500 mg/kg/day for 28 days.
Toxicokinetics and liver drug concentrations. A satellite group of rats (n ¼ 3/group) were designated for toxicokinetic analysis and determination of liver drug concentrations. Plasma and liver samples were prepared and processed as described (vide supra).
Clinical chemistry. Blood ($1 mL) was collected at end-of-dose by retro-orbital bleeding, following anesthesia with 70/30% CO 2 /O 2 , into tubes and allowed to clot. Serum was analyzed for standard clinical chemistry parameters using the Siemens Advia 1800 Clinical Chemistry Analyzer (Tarrytown, NY). The remaining serum and liver collected at end-of-dose from rats treated with TAK-875 for 5 days were used for measurement of individual bile acids by LC/MS/MS as described in Supplementary, analytical method 4).
Histopathology. Liver samples collected at necropsy on Day 5 or Day 28 were fixed in 10% formalin prior to embedding in paraffin blocks, sectioned, and stained with hematoxylin and eosin for examination by light microscopy.
Hepatic gene expression analysis. RNA was extracted from livers isolated on Day 5 or Day 28 using Qiagen RNeasy Midi kits. Firststrand cDNA was synthesized using SuperScript VILOTM MasterMix, and amplification conducted using Taqman low density array cards (Applied Biosystems Custom Array) run on Viia7 (Thermo Scientific, Waltham, MA). Data analysis was performed using DataAssist 3.0 (Thermo Scientific) and OmicSoft Array Studio (Cary, NC).
Hepatic Transporter Assays
Hepatocyte studies. Sandwich-cultured rat hepatocytes (SCRH) were obtained from Qualyst (Durham, NC). B-CLEAR Transporter Certified cryopreserved human hepatocytes were obtained from KaLy-Cell (France) and a Cell-Less B-CLEAR Kit was purchased from Qualyst (Durham, NC). Taurocholate (1 mM) was used as a substrate for (NTCP/Ntcp) and BSEP/Bsep, and 1 mM estradiol-b glucuronide was used as a substrate for human and rat organic anion transporters (OATP/Oatp) and MRP2/ Mrp2. Vesicles. Membrane vesicles from human BSEP-, MRP2-, MRP3-and MRP4-overexpressing HEK293 cells or rat Mrp3-and Mrp4-were purchased from PharmTox Radboudumc (Nijmegen, The Netherlands). 1 mM
H-estradiol-b glucuronide, and 1 mM 3 H-dehydroepiandrosterone sulfate (DHEAS) were used as probe substrates for BSEP, MRP2, MRP3/Mrp3/4, and MRP4, respectively. Transporter inhibition experiments were conducted as previously described (Morgan et al., 2013) .
Mitochondria Respiration Assay in HepG2 Cells
Cellular respiration in intact cells was measured using a Seahorse XF e 96 analyzer (North Billerica, MA). HepG2 cells were seeded in
Seahorse XF e 96-well culture plates at 40 000 cells/well in EMEM þ 10% FBS growth medium and allowed to adhere overnight. The mitochondrial stress assay was conducted as described by the manufacturer in optimized Seahorse media containing 5.5 mM glucose, 16 mM glutamine and 8 mM pyruvate under protein-free conditions. Oxygen consumption rates (OCR) were measured following treatment with TAK-875 and TAK-875AG at 0.1-100 lM.
Mitochondria Respiration Assay Using Isolated Rat Liver Mitochondria
Mitochondria were isolated from rat liver (2 g) as previously described (Will et al., 2006) . Oxygen consumption was measured using a StrathKelvin RC650 Respirometer (North Lanarkshire, Scotland). Reactions were conducted by sequential addition TAK-875 (3-100 lM), followed by 12.5 mM glutamate/maleate or 25 mM succinate, and finally 2.5 mM ADP to freshly isolated rat liver mitochondria (1.5 mg/mL). A ratio of State III, maximal respiration after addition of ADP, to State IV, ADP-independent respiration after addition of substrate only, was calculated.
RESULTS
In Vitro Metabolism of TAK-875 in Rat, Dog, Cyno, and Human Hepatocytes The metabolites of TAK-875 have been reported in human and in vitro Naik et al., 2012) ; notably it forms the oxidative metabolite M-I, the AG (TAK-875AG), and the taurine conjugates (TAK-875TAU), each of which were also formed in rats, dogs, cyno, and human cryopreserved hepatocytes. There was low turnover of TAK-875 (T 1/2 > 100 min, 88% remaining, 4 h incubation) across all species (Supplementary Table 1) , which was consistent with literature reports (Negoro et al., 2010) . Additional metabolites observed included an AG metabolite of M-I and a monooxy-TAK-875. The rank order of formation of TAK-875AG in hepatocytes was dog % cyno > human o rat.
Covalent Binding Studies to Identify Reactive Species of TAK-875
Experiments were conducted to investigate whether TAK-875 formed reactive metabolites based on the schematic outlined in C-TAK-875 in the presence of the pan-P450 inhibitor ABT did not attenuate covalent protein binding ( Table 1 ), suggesting that oxidative metabolism does not contribute to reactivity of TAK-875, whereas incubation with (-)-borneol, an inhibitor of the UDPglucuronosyltransferase (UDP-GT) pathway, reduced covalent binding by $40% (Table 1) , implicating TAK-875AG as the reactive species. The partial inhibition in reactivity was accompanied by $90% reduction in the formation of TAK-875AG, suggesting that other pathways, possibly the formation of TAK875CoA (Figure 1 ), may also contribute to reactivity of TAK-875. Trace levels of TAK-875CoA and its downstream metabolite TAK-875TAU were detected in human hepatocytes (data not shown). Covalent binding by diclofenac, included as a positive control, was inhibited by ABT and (-)-borneol (Table 1) , which is in agreement with published reports (Boelsterli, 2003) . The covalent binding burden (CVB) for TAK-875 calculated as described by Thompson et al. (2012) using the clinical dose of 50 mg, was 2.0 mg/day, compared with 3.8 mg/day and 8.9 mg/day for diclofenac and troglitazone, respectively (Table 1) . Detection of acyl migrated products of TAK-875-AG further confirmed its reactivity (data not shown). The chemical degradation half-life of the AG metabolite, a surrogate for reactivity of AGs (Sawamura et al., 2010) , was 0.5 h for TAK-875AG (Supplementary and was within the same range as for the AG metabolites of diclofenac (0.7 h) and zomepirac (0.4 h), and other reported unstable AG metabolites with a high risk of idiosyncratic reactions (Lassila et al., 2015; Sawamura et al., 2010) . AG metabolites with a chemical degradation half-life ! 7 h are generally safe.
In Vivo Metabolism of TAK-875 in Rats, Dogs, and Cynos The metabolites of TAK-875 reported in human were also formed in rats, dogs, and cynos following single oral administration of TAK-875 (Table 2 ). The major human metabolite M-I, detected at 10% of parent AUC, was also detected at 10% in rats and cynos, but at 0.5% in dogs. Appearance of TAK-875AG in plasma was 0.26%, 2.6%, and 18% of parent AUC in rats, dogs, and cynos, respectively, and, further, the dose-normalized AUC were $6-fold greater in dogs and cynos compared with rats. TAK-875AG was detected in liver with a liver/plasma ratio of 14 and 23 in rats and dogs, respectively (Table 2) ; the dosenormalized concentrations of TAK-875AG in liver were 3-fold greater in dogs compared with rats. These results show that rank order of TAK-875AG formation in plasma and/or liver is in the order of dogs % cynos > rats, and is consistent with the rank order in its formation in vitro (vide supra). Both TAK-875 and TAK-875AG are eliminated in bile based on significant concentrations detected in bile collected from dogs (Table 2) . TAK-875TAU was detected in Covalent binding burden calculated as described by Thompson et al (2012) . **P < .05 (One-Way ANOVA). greater amounts in rats compared with dogs or cynos ( Table 2) . Detection of TAK-875TAU provides indirect evidence that the acyl CoA thioester TAK-875CoA is formed in vivo.
Toxicity Assessment of TAK-875 in Rats
Repeat-dose studies in rats were conducted to provide mechanistic insight on the role of reactive AG on TAK-875-mediated liver toxicity, given its detection in liver following single-dose administration.
Toxicokinetics and liver drug concentrations. Treatment of rats with TAK-875 at 100, 300, and 1000 mg/kg/day for 5 days, or at 500 mg/kg/day for 28 days, resulted in significant amounts of TAK-875 and TAK-875AG in plasma and liver (Table 3) . Exposure to TAK-875 in plasma increased with dose, but was less than dose-proportional, whereas exposure to TAK-875AG was greater than dose-proportional from 300/500 to 1000 mg/kg/day ($Â8). Liver concentrations of TAK-875 (C 24 h ) were greater than doseproportional (Â7.3) from 300 mg/kg/day to 1000 mg/kg/day, or to 500 mg/kg/day (Â2.7) after 28 daily doses. Liver concentrations of TAK-875-AG (C 24 h ) were generally similar at 100/300/500 mg/ kg/day but were greater than dose-proportional ($Â8) between 300 and 1000 mg/kg/day. TAK-875TAU was also present in liver up to concentrations of 8.96 lg/g (14 lM) at 1000 mg/kg/day.
Clinical chemistry. Treatment with TAK-875 resulted in a doserelated and significant increase in ALT at 300 (1.7-fold) and 1000 mg/kg/day (4-fold) on Day 5, and at 500 mg/kg/day (2.2-fold) on Day 28 (Figure 2A ). Increases in AST were significant only at the high dose on Day 5. There was also a dose-related increase in total bilirubin (up to 9-fold), on Days 1 and 5 compared with vehicle-treated rats, and on Day 28 at 500 mg/kg/day ( Figure 2B ). Elevated bilirubin, following fractionation, was found to be predominantly the conjugated (UDP-GT mediated) form. Total bile acids increased in a dose-related manner up to 3.4-fold on Day 1, and although remained elevated, were generally variable on Day 5 ( Figure 2C ). Bile acid fractionation of serum samples revealed significant increases in circulating cholic acid (CA), muricholic acid (MCA), and taurine conjugated bile acids including taurocholic acid (TCA; Supplementary Figure 1) at the highest dose. Fractionation of bile acids in liver from the same rats found dose-related decreased concentrations in several bile acids including deoxycholic acid (DCA) and its taurine conjugate (TDCA) and glycine/taurine conjugates of CA.
Histopathology. Liver was identified as the only drug-related target organ with findings limited to the highest dose coinciding with high concentrations of TAK-875 and TAK-875AG. Minimal to mild hepatocellular hypertrophy was observed at 300 and 1000 mg/kg/ day on Day 5 (Table 3, Supplementary Figure 2) and at 500 mg/kg/ day on Day 28 (Table 3) . Hypertrophy was distributed to both centrilobular and periportal regions on Day 5, and to periportal region on Day 28, and were associated with increased amounts of granular eosinophilic cytoplasm and single-cell necrosis in the subcapsular region. Hepatocellular hypertrophy on Day 5 was accompanied by macroscopic findings of enlarged liver, increased liver weights (up to 33%) and induction in Cyp3a1 (Â16) on Day 5 (Table 4) , whereas periportal hypertrophy at 500 mg/kg/day on Day 28 were not accompanied with increased liver weights, but rather with minimal increases in Cyp3a1 (Â2.7).
Gene expression. A previously described oxidative stress/reactive metabolite gene signature (McMillian et al., 2004) for DILI compounds was significantly induced by TAK-875 at 300 and 1000 mg/ kg/day (Table 4 ). There was also increased expression of Mrp3 (Â19) and Oatp1a (Â4), as well as UGT (Â3-9), likely associated with disposition of TAK-875, and increases in several genes involved in fatty acid synthesis and disposition (data not shown).
Inhibition of Rat Hepatic Transporters by TAK-875
TAK-875 inhibited rat uptake (Oatp1, Ntcp) and efflux (Mrp2, Bsep) transporters with IC50s of 1-13 lM (Table 5 ). This may be relevant in rats given TAK-875 at 300-1000 mg/kg/day based on derived free plasma and liver concentrations of up to 2 lM, assuming similar protein binding for TAK-875 in liver as in plasma (rat plasma protein binding; 99.86%). TAK-875 also inhibited rat Mrp3 and Mrp4 at 29 and 35 lM, respectively. TAK-875AG inhibited rat uptake transporters with IC50s of 2-8 lM; these inhibitions are likely not relevant in vivo because of low free plasma concentrations of TAK-875AG (<37 nM) based on rat plasma protein binding of 99.74%. Liver concentrations of TAK-875AG can reach up to 32.7 lM (23 lg/g) at doses tested, which Figure 2 . A, Alanine and aspartate aminotransferase activities in rats treated with TAK-875 at 0 (vehicle), 100, 300, and 1000 mg/kg/day for 5 days or 500 mg/ kg/day for 28 days. B, Total bilirubin in rats treated with TAK-875 at 0 (vehicle), 100, 300, and 1000 mg/kg/day for 1 and 5 days or 500 mg/kg/day for 28 days. C, Total serum bile acids in rats treated with TAK-875 at 0 (vehicle), 100, 300, and 1000 mg/kg/day for 1 and 5 days or 500 mg/kg/day for 28 days.
could be sufficient to inhibit Mrp2 (IC50:35 lM) and Mrp3 (IC50:0.82 lM; Table 5 ). Collectively inhibition of these transporters by TAK-875 or TAK-875AG may partially explain observed increases in bilirubin and bile acid in rats (Figure 2) . Inhibition of these transporters could also explain the non-linear accumulation of TAK-875AG in liver from lower doses to high dose, likely due to saturation of biliary efflux of TAK-875AG because glucuronides are known substrates of Mrp transporters.
Inhibition of Human Hepatic Transporters by TAK-875
TAK-875 and TAK-875AG generally had similar potencies ($within 3-fold) for human uptake transporters (OATP1, NTCP) and the efflux transporters MRP2 and MRP4 (Table 5 ). Both compounds were weak BSEP inhibitors, and TAK-875AG was $10-fold more potent at MRP3 than TAK-875. Notably, TAK-875 and TAK-875AG were more potent at human MRP2 ($10-fold) and MRP4 ($10-50-fold) than the corresponding rat transporters, whereas TAK-875AG had similar potency for rat Mrp3 and human MRP3. TAK-875AG inhibited MRP2, 3, and 4, with an IC50 of 1, 0.21, and 0.87 lM, respectively, indicating that inhibition of these transporters may contribute to accumulation of this metabolite in liver.
Inhibition of Mitochondrial Respiration by TAK-875
Potential for mitochondrial dysfunction by TAK-875 and TAK-875AG was evaluated by measuring oxygen (O 2 ) consumption in HepG2 following treatment using the Seahorse platform, or in isolated rat mitochondrial preparations using a Respirometer. TAK-875 was not cytotoxic to hepatocytes or HepG2 cells following incubations of up to 100 lM for 72 h (data not shown). TAK-875 caused a concentration-dependent inhibition of basal O 2 consumption rate ( Figure 3A and B) , ATP production, and maximal respiratory capacity in HepG2 cells with an IC50 of 17, 8.8, and 28 lM respectively. TAK-875AG had no effect on basal respiration and ATP production in HepG2 cells and inhibited maximal respiratory capacity with an IC50 of $49.5 lM, therefore the effect of the metabolite on mitochondria was not considered meaningful. Mechanistic studies conducted in isolated rat mitochondria identified the enzymes NADH dehydrogenase (Complex 1) and succinate dehydrogenase (Complex 2) as targets for inhibition by TAK-875 ( Figure 3C ) with IC50s of 17 lM and 28 lM, respectively.
DISCUSSION
TAK-875, a GPR40 agonist, was voluntarily withdrawn from Phase III clinical trials by the study sponsor Takeda due to concerns of liver safety. Recent publications describe increases in transaminases in patients given TAK-875 in 24-week and 52-week Phase III clinical trials that were considered drugrelated (Kaku et al., 2015 (Kaku et al., , 2016 . The occurrence of DILI appears delayed at onset and may be idiosyncratic in nature. Currently, there are no reliable animal models for predicting iDILI, however, several hazards that can be used to build a weight of evidence for assessing a compound's risk for DILI have been identified. This approach was taken to retrospectively identify DILI hazards for TAK-875. Formation of reactive metabolites and covalent binding to proteins is recognized as a DILI hazard based on potential for immune activation. TAK-875 is a carboxylic acid that forms an AG metabolite, a species that has been associated with idiosyncratic reactions linked to reactivity (Lassila et al., 2015; Sawamura et al., 2010) . However, AGs of carboxylic acids have diverse range of chemical reactivity. A comparison of chemical degradation half-lives (T 1/2 ) of AGs for several carboxylic acids established a rank order between T 1/2 and risk for idiosyncratic reactions; compounds with short AG T 1/2 were more prone to cause idiosyncratic reactions compared with those with longer T 1/2 . Using similar methods, the AG T 1/2 of TAK-875 was found to be within the same range as that of zomepirac, which was withdrawn, and diclofenac, which has a serious warning for idiosyncratic reactions.
Using radiolabeled compound, and methods described by Thompson et al. (2012) , it was confirmed that TAK-875 was indeed reactive based on its covalent binding to proteins, a more definitive measure of reactivity. Studies in hepatocytes using inhibitors of CYP450s and UDP-UGT pathway concluded that the covalent protein binding by TAK-875 was partially due to formation of a reactive AG, without any contribution by CYP450-mediated oxidative metabolism. The CVB of TAK-875, a measure that takes into consideration the clinical dose, binned the compound as a high DILI risk based on an exposure threshold established by Thompson et al. (2012) . Carboxylic acids can also be bioactivated to form acyl CoA thioester intermediates (Darnell and Weidolf, 2013) , therefore contribution of this pathway to reactivity of TAK-875 cannot be ruled out. Gene expression profiling in rats following treatment of TAK-875 also identified a previously described reactive metabolite gene signature (McMillian et al., 2004) , further confirming reactivity of TAK-875.
The in vitro formation of TAK-875AG and TAK-875TAU, a downstream metabolite for the reactive TAK-875CoA, was bridged to in vivo, based on their detection in plasma, liver, and bile in rats and non-rodents. The rank order for formation of TAK-875AG suggests that rats form less TAK-875AG than nonrodents (dogs, cynos) and humans. Glucuronidation was also described as the major metabolic pathway for TAK-875 in humans (Kaku, 2013) . It can be postulated that liver AG concentrations associated with toxicity in non-clinical models could be a relevant benchmark for clinical risk, and that these concentrations may be reached at higher doses in rats than in nonrodents or humans.
Indeed, liver was identified as a target organ for toxicity in rats, but only at a high dose of TAK-875 that was coincident with high plasma and liver concentrations of TAK-875AG. Glucuronides, including drug glucuronides and endogenous glucuronides (e.g., bilirubin glucuronide) are substrates for MRP2 and MRP3 hepatic transporters (van der Schoor et al., 2015) . Onset of findings in rats coincided with a dose where biliary efflux of AG was saturated, likely from inhibition of Mrp2, resulting in high concentrations of AG in liver. This is supported by biliary elimination studies that confirmed biliary efflux of TAK-875AG in rats and dogs. Findings in rats at the high dose consisted of hepatocellular hypertrophy in the periportal and centrilobular region accompanied by granular eosinophilic cytoplasm and single-cell hepatocyte necrosis along with increases in ALT (Â4), bile acids Â3.4), and bilirubin (Â9). Hypertrophy, especially in the centrilobular region, is likely a result of Cyp3a1 induction and may be rodent-specific, but the role of mitochondria on periportal hypertrophy cannot be ruled out, given in vitro data showing that mitochondria is a target organelle for TAK-875. Hepatocytes in the periportal region have a higher density and larger mitochondria than those in the centrilobular region, and the periportal region is also the site for the final oxidation of acetyl CoA during oxidative phosphorylation; in addition, enzymes involved in these metabolic pathways, including alanine transaminase, are also localized in the periportal region (Jungermann and Katz, 1989) . Increases in circulating conjugated bilirubin (bilirubin glucuronide) and bile acids in rats following treatment with TAK-875 may partially be explained by inhibition of the uptake transporters Oatp1b (substrate: bilirubin glucuronide) and Ntcp (substrate: taurocholate) or the efflux transporters Bsep (substrate: taurocholate) and Mrp2 (substrate: bilirubin glucuronide). Mrp3 overexpression (Â19) in rats at the high dose is an expected adaptive response that has been described in man and rodents following defects in Mrp2 activity or cholestasis as a means for clearing hepatocytes of bilirubin or bile acids (van der Schoor et al., 2015) , therefore its induction may have contributed to the increases in conjugated bilirubin and bile acids in plasma and decreases in bile acids in liver after repeated dosing.
Findings in rats may be relevant for human risk assessment because rodents form less AG than non-rodents and humans (in vitro data) hence liver AG concentrations could be higher in man at lower doses than in rats, and could be even greater in individuals with impaired MRP hepatic transporters; several polymorphisms in MRP2 and MRP3 transporters that impact their function have been described (van der Schoor et al., 2015) . In addition, TAK-875AG is significantly more potent at human MRP2/3/4 (0.21-1 lM) transporters at concentrations that could be reached at clinically relevant doses compared with the corresponding rat transporters, further lending support that liver AG accumulation, resulting from inhibition of its efflux, could occur at lower doses in man than in rats. TAK-875AG was considered to be important for human DILI risk assessment because of its reactivity and the observation that onset of findings in rats coincided with a dose where retention of TAK-875AG in liver was significant.
With regards to the human relevance of hepatic transporter inhibition, the estimated free plasma concentrations (14 nM) of TAK-875 (human protein binding: 99.84%) at the clinical dose of 50 mg (C max : 10 lM) is unlikely to have any significant inhibition on the uptake transporters NTCP and OATP1B (IC50s; 1-5 lM). It can be speculated that liver concentrations of TAK-875 and TAK-875AG above their MRP2/3/4 IC50 may, with time, cause accumulation of both compounds in liver and the significance of inhibition of these transporters has been discussed (vide supra). Both TAK-875 and TAK-875AG were significantly less potent at human BSEP in sandwich culture and vesicle assays (IC50: 23 to >50 lM) compared with MRP2/3/4 (0.2-1 lM); the clinical relevance of BSEP inhibition is unclear. Nevertheless, liver concentrations of drug or metabolite above BSEP IC50 could cause accumulation of toxic bile acids. Extrapolating from the non-clinical studies where liver to plasma ratio for TAK-875AG is > 10 suggests that liver accumulation of TAK-875AG may also occur in man.
Because clinical translational markers for inhibition of mitochondrial respiration are lacking, the in vivo relevance of in vitro inhibition of mitochondrial function is often challenging to assess unless there is overt toxicity. As such, in vitro inhibition of mitochondrial respiration by TAK-875 can only be categorized as a hazard, and the IC50/C max ratio ($1.7) bins it as a DILI risk based on criteria described by Shah et al. (2015) . Furthermore, inhibition of mitochondrial respiration may exacerbate hepatic transporter inhibition (Aleo et al., 2014) , which could enhance liver retention of the AG metabolite or bile acid accumulation due to BSEP inhibition. In addition, mitochondrial-induced cell stress may trigger release of DAMPs and provide the danger signal to trigger an adaptive immune attack (Uetrecht, 2008) . Findings from the studies described in this paper have a broader application for other GPR40 agonists because the majority of molecules described thus far require a carboxylic acid functional group for pharmacological activity (Defossa and Wagner, 2014) and will form acylglucuronides as a class; these findings can also be applied to other compounds that have the potential to form a reactive AG. Acyl glucuronides are traditionally not considered to be major contributors to iDILI, but these studies suggest that their efflux by hepatic MRP transporters limit their retention in liver, and that they can pose a risk for DILI when they are very reactive and their hepatic efflux is attenuated.
A strategy that can be considered during clinical development of compounds that form a reactive AG metabolite with a DILI concern is to identify doses where the metabolite is likely to accumulate in liver in order to establish a threshold below which there may be a reduced risk for DILI. Monitoring of AG concentrations can be coupled with functional measures of hepatic transporter inhibition, for example, rise in serum bile acids (taurocholate) or conjugated bilirubin as described in the rat studies. Given the obvious challenges for measuring liver AG concentration in the clinic, monitoring of plasma AG levels or use of technologies, such as Entero-Test (Bloomer et al., 2013) to monitor biliary concentrations of AG in humans may be useful surrogates for identifying doses where biliary efflux of AG is saturated signifying probable liver AG accumulation. A greater than dose-proportional and non-linear formation of TAK-875AG in plasma and liver observed at the high dose in rats confirms that plasma AG concentrations may be a suitable surrogate for monitoring potential for saturation in biliary AG efflux for some compounds.
Potential contribution of MRP2 and MRP3 polymorphisms or absence of MRP2 (Dubin-Johnson syndrome; van der Schoor et al., 2015) to the disposition and liver burden of reactive acylglucuronides may also be considered during clinical development of compounds that form reactive AGs. Genotyping for these polymorphisms and mutations could be informative in developing an association between variants of these transporters and DILI.
In conclusion, as illustrated in schematic in Figure 4 , our investigation points to formation of reactive TAK-875AG, inhibition of hepatic transporters, and inhibition of mitochondrial respiration as key mechanisms that may contribute to nonimmune and/or immune-mediated DILI by TAK-875. Formation of TAK-875AG in liver coupled with inhibition of MRP2/3/4 likely contributes to retention of the reactive intermediate in liver via saturation of its efflux. These DILI hazards can be used in a weight of evidence approach for differentiation of future generation GPR40 agonists.
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